Bridgefront Capital’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$436K Buy
+12,282
New +$371K 0.1% 304
2021
Q2
– Sell
-2,994
Closed -$205K – 648
2021
Q1
$205K Buy
+2,994
New +$225K 0.06% 579

Other funds holding CSTL

Bridgefront Capital's CSTL Position: Q3 2026 in Review

Bridgefront Capital opened a new position in Castle Biosciences (CSTL) in Q3 2026: 12,282 shares worth $436K. The stake represents 0.1% of the portfolio and ranks #304 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in CSTL as recently as Q1 2021.

Bridgefront Capital first reported a position in CSTL in Q1 2021 and has held it in 2 quarters since. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Bridgefront Capital held 12,282 shares of Castle Biosciences worth $436K as of Q3 2026.
  • Castle Biosciences was a new Bridgefront Capital position in Q3 2026.
  • Castle Biosciences made up 0.1% of Bridgefront Capital's portfolio in Q3 2026, its #304 holding.
  • Bridgefront Capital first reported a position in Castle Biosciences in Q1 2021 and has held it in 2 quarters since.
  • 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Bridgefront Capital's 13F filing for Q3 2026, filed 16 Nov 2026.